checkAd

     214  0 Kommentare New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium

    Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium in San Francisco on Oct. 11.

    The ASPORS meeting marks the first time that detailed secondary endpoint outcomes from the teprotumumab OPTIC trial related to diplopia (double vision), Graves’ Ophthalmopathy (GO) Quality of Life and clinical activity score (CAS) will be presented. CAS is a 7-point scale that quantifies the pain, redness and swelling of various eye tissues. Posters about the perceptions and burden of thyroid eye disease (TED) will also be presented.

    Presentation Details:

    “Teprotumumab Infusions Reduce Proptosis in Thyroid-Eye Disease in a Randomized, Placebo-Controlled, Clinical (OPTIC) Study: Effectiveness on Diplopia and other Secondary Outcomes”

    • Speaker: Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center
    • Session: Thyroid Eye Disease
    • Date: Friday, Oct. 11, 2019
    • Time: 9:14 a.m. Pacific Time

    “Physician Perceptions of Active Thyroid Eye Disease in the United States”

    • Lead Author: Yao Wang, M.D., Cedars-Sinai Medical Center
    • Session: Digital Poster and Video Viewing
    • Date: Thursday, Oct. 10
    • Time: 6:45 a.m. Pacific Time

    “Impact of Thyroid Eye Disease on Patient Quality of Life as Perceived by US Ophthalmologists”

    • Lead Author: Yao Wang, M.D., Cedars-Sinai Medical Center
    • Session: Digital Poster and Video Viewing
    • Date: Thursday, Oct. 10
    • Time: 6:45 a.m. Pacific Time

    About Thyroid Eye Disease

    Thyroid eye disease (TED) is a serious, progressive and vision-threatening autoimmune disease with a limited window of activity that can last up to three years.1,2,3 While TED often occurs in people living with hyperthyroidism or Graves’ disease, it is a distinct disease that is caused by autoantibodies activating an IGF-1R-mediated signaling complex on cells within the orbit.4,5 This leads to a cascade of negative effects, which may cause long-term, irreversible damage. Active TED lasts for up to three years and is characterized by inflammation and tissue expansion behind the eye.1,6 As TED progresses, it causes serious damage – including proptosis (eye bulging), strabismus (misalignment of the eyes), and diplopia (double vision) – and in some cases can lead to blindness.2,7 TED has only been shown to respond to pharmacotherapy while the disease is active and inflammation is ongoing.8 Currently, patients must live with active TED until the disease becomes inactive – often left with permanent and vision-impairing consequences.1,6

    Seite 1 von 3


    Business Wire (engl.)
    0 Follower
    Autor folgen

    New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive …